The eye is one of the most sensitive organs that can be injured by toxic chemicals and warfare agents, but drug treatments to mitigate chemical-induced ocular pathology have not been developed. Alerted to increased threats posed by homeland terrorists who could cause mass casualty by chemical exposure, the trans NIH-agency CounterACT program was developed to fund cutting-edge research to combat bodily injury (https://www.ninds.nih.gov/current-research/trans-agency-activities/counteract-program.) Dr. Mohan is a recipient of a National Eye Institute grant titled “Unraveling the corneal and retinal mechanisms of chemical injury” to expand his research on novel therapeutic targets in the eye for such chemical emergencies.
